alexa Progestins/Antiprogestins: Role in Pathogenesis and Treatment for Endometriosis | OMICS International
ISSN: 2161-0932
Gynecology & Obstetrics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Progestins/Antiprogestins: Role in Pathogenesis and Treatment for Endometriosis

Shylesh S. Bhaskaran and Hareesh B. Nair*

Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio TX 78227, USA

*Corresponding Author:
Hareesh B. Nair
Southwest National Primate Research Center
Texas Biomedical Research Institute
7620 NW Loop 410
San Antonio TX 78227, USA
Tel: 210-258-9515
Fax: 210-258-9883
E-mail: [email protected]

Received date: May 29, 2012; Accepted date: May 29, 2012; Published date: May 31, 2012

Citation: Bhaskaran SS, Nair HB (2012) Progestins/Antiprogestins: Role in Pathogenesis and Treatment for Endometriosis. Gynecol Obstet 2:e105. doi: 10.4172/2161-0932.1000e105

Copyright: © 2012 Bhaskaran SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Gynecology & Obstetrics


Endometriosis is a painful gynecological condition in the fertile-age in which presence of endometrial tissue develops outside the uterus, which under normal situation found only in the inside lining of the uterus, attach to pelvic floor, endometrium or peritoneal cavity. Endometriosis cause abdominal pain, bleeding, irregular menstrual cycles with excessive pain, inflammatory responses and infertility. Retrogressive menstruation and invasion theories have been well studied in the pathogenesis of endometriosis. Role of steroids including estrogen, gonadotropin releasing hormones has been documented and major treatment strategies are based on steroid biology of endometriosis. Current treatment strategies are less successful and solely focusing on the late phase of the disease. The exact role of progesterone in the initiation (initial phase) of endometriosis has not been well studied or overshadowed by the concept of progesterone resistance that occurs in late phase in endometriosis. In this review, we are discussing the role of progesterone and potential use of anitprogestins or possible combination treatment strategies which may help to combat initiation and progression of endometriosis.


Endometriosis; Progesterone; Antiprogestins; Focal adhesion kinase (FAK); Personalized therapy

Endometriosis is a benign gynecological disease that affects about 10% of reproductive age women associated with pelvic pain and remains as a notable reason for infertility [1]. Patients with endometriosis also show reduced rates of follicular growth, reduced functional ability of the pre-ovulatory follicle, reduced fertilization rates, irregular preimplantation embryonic development, altered early luteal function and reduced implantation rates [2,3]. Classical treatments include progestins and antiestrogens and GNRH antagonists, often lead to undesirable side effects and compromising quality of life [4]. Endometriosis is expensive to treat and complex to study because there are notable delays in the diagnosis and variations in symptoms and disease development in patients [5]. Also, at the time of clinical presentation, most women have established disease, making the initiation of endometriosis is difficult to study. The implantation hypothesis of retrograde menstruation by Sampson [6] is the most widely accepted theory of endometriosis. Although retrograde menstruation occurs in all women, the reason for adhesion and invasion of endometriotic epithelial and stromal cells on peritoneal mesothelium in only 10% of women remain elusive.

Only sparse reports are available regarding the molecular signalling of endometrial pathogenesis leading to the initiation and progression of endometriosis. A Large body of scientific evidence suggests that estrogen and Estrogen Receptors (ERs) are involved in progression of endometriosis [7]. Although progestins are used to treat endometriosis, the exact role of progesterone in the formation (initiation) of endometriotic lesions is poorly understood. The main side effects of progestin therapies are interim bleeding, weight gain and reduced libido. Oral contraceptives are generally well tolerated but they are not as effective in reducing pain [8]. GnRH-antagonists are highly effective but they lead to a significant reduction in bone density [9]. Progesterone is produced by the corpus luteum to maintain early pregnancy. Low progesterone secretion in the luteal phase has been associated with habitual abortion. Hence it is logical to hypothesize that antiprogestins given in early pregnancy can act as abortifaciants and could provide alternative to surgical abortion.

Based on our laboratory experiments, progression of endometriosis were primarily depends on the levels of progesterone secretion by the corpus luteum at the time of attachment of menstrual endometrial epithelial/stromal cells to peritoneal mesothelium. Progesterone level is maintained high enough to support the attachment, subsequent invasion and then dramatically drops after 1-2 weeks. This window period is very crucial for progesterone induced proliferation and activation of progesterone target genes to ease the cellular invasion of the attached menstrual endometrial or stromal cells. Hence we point out that endometriosis is a pseudo-pregnancy state and the corpus luteum produces progesterone to support and maintain the attached endometrial/stromal cells as if it were a fertilized egg. In most clinical cases at the time of diagnosis (2-6 months), the circulating as well as tissue levels of progesterone are too low to be detected and often misunderstood as progesterone resistance [10,11].

Another important aspect in the context of the ideal profile of an antiprogestin for endometriosis is its effect on the endometrium [12]. The endometrium is under a well balanced control of estrogens and progestins. Estrogens lead to a strong proliferation of the endometrium that might lead to endometrial hyperplasia if this effect is not controlled through the antiestrogenic effect of progestins. Sustained, persistent estrogenic stimulation in the absence of progestin ultimately results in hyperplasia. Our results pointing the fact that effect of estrogen is apparent only in the second phase of the disease (unpublished data), since the first wave of progesterone secretion by the corpus luteum to support the pseudo egg is sufficient to initiate the menstrual endometrial/stromal cell attachment on the peritoneal mesothelium. The treatment with a pure antiprogestin may therefore inhibit menstrual endometrial/stromal cell attachment on peritoneal mesothelium and also may inhibit the subsequent second wave of estrogen induced proliferation.

Currently, RU 486 (Mifepristone) is the first and most widely studied antiprogestin. At the present time, it has been approved only for termination of second trimester pregnancies [13]. The long term application of Mifepristone is hampered due to its strong antiglucocorticoid effect [14]. Newer antiprogestins, CDB 4124, also known as Proellex®, was found to be 2.8 fold more potent than RU 486 without exhibiting any agonistic activity. The antiglucocorticoid activity was determined to be around 1/3 of that of Mifepristone [15]. The phase II clinical study evaluating the safety and efficacy of the selective progesterone receptor modulator Proellex® (CDB-4124) in the treatment of premenopausal women with symptomatic endometriosisextension study was discontinued due to adverse events (Clinical trials. gov; NCT00958412). There is unmet need for a better understanding of the role of progesterone in the initiation and progression of endometriosis that will expand our knowledge to develop better antiprogestins for the safer treatment of endometriosis with minimal or no anti-glucocorticoid side effects.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 2nd World Congress on Embryology and In Vitro Fertilization March 30-31, 2018 Orlando, USA. Theme: Exploring the Novel Research & Techniques in Reproductive Health
    March 30-31, 2018 Orlando, USA
  • World Congress on Gynecology and Obstetrics
    April 16-17, 2018 Dubai, UAE
  • 7th International Conference on Clinical and Medical Case Reports June 01-02, 2018 Osaka, Japan Theme: Focusing the breakthroughs of case reports in Clinical & Medical Research
    June 01-02, 2018 Osaka, Japan
  • 7th International Conference and Exhibition on Surgery June 21-23, 2018 Dublin, Ireland Theme: Advancements and Endeavours in the Field of Surgery
    June 21-23, 2018 Dublin, Ireland Dublin, Ireland
  • Annual Congress on Research and Innovations in Medicine July 02-03, 2018 Bangkok, Thailand Theme: Current Research and Innovations in Medicine to Improve Human Health
    July 02-03, 2018 Bangkok, Thailand
  • International Conference on Medical and Health Science August 24-25, 2018 Tokyo, JAPAN Theme: Scrutinize the Modish of Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • World Summit on Trauma and Reconstructive Surgery Sep 10-11, 2018 Singapore Theme: Expanding new horizons in Trauma and Surgery
    Sep 10-11, 2018 Singapore City, Singapore
  • 6th American Gynecological Surgery Conference September 28-29, 2018 San Antonio | Texas | USA
    September 28-29, 2018 San Antonio, USA
  • World Congress on Fetal and Maternal Medicine October 15-17, 2018 Osaka, Japan Theme: A New Beginning on Fetal, Maternal & Neonatal Medicine
    October 15-17, 2018 Osaka, Japan
  • International Conference on Reproduction and Fertility October 18-19, 2018 Abu Dhabi, UAE
    October 18-19, 2018 Abu Dhabi, UAE

Article Usage

  • Total views: 11774
  • [From(publication date):
    June-2012 - Jan 22, 2018]
  • Breakdown by view type
  • HTML page views : 8000
  • PDF downloads : 3774

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version